RxDoctor Payments Data

Gregory Eaves, MD

Cardiovascular Disease · Aiken, SCNPI 1487737821

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $54,587 of the $64,741 with a category attached, or 84.3%. Novo Nordisk accounts for 77.0% of it on its own, with 45 other manufacturers making up the rest. Reporting peaked in 2023 at $27,887 and has fallen 82.8% since, to $4,786 in 2025. Among cardiovascular disease clinicians in SC with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$64,741in general payments, 2019–2025

Across 308 payments — averaging $210.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$50K
  • Amgen$10K
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$878
  • Inari Medical, Inc.$571
  • Boston Scientific$563
  • Abbott$462
  • plus $3K from 40 others

What the payments were for

  • Consulting fees$2,1153%
  • Speaking & faculty fees$54,58784%
  • Travel & lodging$2,1343%
  • Food & beverage$5,8479%
  • Education$580%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$64,741 in reported general payments places this provider in the 95th percentile of 257 cardiovascular disease providers in South Carolina.

See all cardiovascular disease providers in South Carolina

Medicare billing

Part B allowed, 2024
$159,141
Medicare patients
820
Services billed
1,549

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban773$680,895
EntrestoSacubitril/Valsartan305$289,166
XareltoRivaroxaban177$191,056
OzempicSemaglutide127$132,989
FarxigaDapagliflozin Propanediol88$70,702
JardianceEmpagliflozin67$64,045
MultaqDronedarone Hcl45$37,750
RybelsusSemaglutide32$31,782
Repatha SureclickEvolocumab32$31,372
MounjaroTirzepatide29$27,027
WegovySemaglutide19$24,839
Repatha PushtronexEvolocumab29$21,695
Droxidopa13$14,605
Ranolazine ErRanolazine90$13,262
DapagliflozinDapagliflozin Propanediol22$12,705

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$146$680,895773 claims
NovartisEntresto$269$289,166305 claims
Johnson & JohnsonXarelto$201$191,056177 claims
Novo NordiskOzempic, Rybelsus, Wegovy$49,869$189,610178 claims
AstraZenecaFarxiga, Brilinta$233$82,385111 claims
Boehringer IngelheimJardiance, Synjardy Xr$131$74,08482 claims
Sanofi-aventis U.S. LLCMultaq$67$37,75045 claims
Lilly USA, LLCMounjaro$72$27,02729 claims
Arbor Pharmaceuticals, Inc.Edarbyclor$59$7,25811 claims
AmgenCorlanor$9,583$7,19812 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 257 cardiovascular disease providers in South Carolina.

Other cardiovascular disease in Aiken

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →